Alpine Global Management’s KalVista Pharmaceuticals KALV Stock Holding History

Alpine Global Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,000	Closed	-$145K	–	510
2022 Q3	$145K	Hold	10,000	–	–	0.03%	119
2022 Q2	$98K	Hold	10,000	–	–	0.02%	149
2022 Q1	$147	Hold	10,000	–	–	0.03%	268
2021 Q4	$132K	Sell	10,000 -2,754	-22%	-$43.8K	0.02%	539
2021 Q3	$223K	Buy	+12,754	New	+$258K	0.05%	196
2021 Q2	–	Sell	-10,000	Closed	-$257K	–	338
2021 Q1	$257K	Buy	+10,000	New	+$263K	0.02%	220

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alpine Global Management's KALV Position: Q4 2022 in Review

Alpine Global Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2022, closing a stake of 10,000 shares — an estimated $145K sold.

Alpine Global Management first reported a position in KALV in Q1 2021 and held it in 6 quarters. The position peaked at $257K in Q1 2021. 91 funds tracked by Wall St. Rank hold KALV as of Q4 2022.

Alpine Global Management reported no remaining KalVista Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Alpine Global Management sold 10,000 KalVista Pharmaceuticals shares in Q4 2022, an estimated $145K.
Alpine Global Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Alpine Global Management's KalVista Pharmaceuticals position peaked at $257K in Q1 2021.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2022.

Based on Alpine Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.